MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Cerus Corp

Geschlossen

BrancheGesundheitswesen

1.53 -2.55

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.51

Max

1.54

Schlüsselkennzahlen

By Trading Economics

Einkommen

-5.2M

-7.7M

Verkäufe

-7.6M

43M

EPS

-0.04

Gewinnspanne

-17.85

Angestellte

614

EBITDA

-5.8M

-5.9M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+203.25% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

9.6M

270M

Vorheriger Eröffnungskurs

4.08

Vorheriger Schlusskurs

1.53

Nachrichtenstimmung

By Acuity

50%

50%

146 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Cerus Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. Juli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. Juli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4. Juli 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4. Juli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. Juli 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4. Juli 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. Juli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. Juli 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4. Juli 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4. Juli 2025, 15:49 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4. Juli 2025, 15:49 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4. Juli 2025, 15:49 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole Received All Required Authorizations

4. Juli 2025, 15:48 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4. Juli 2025, 15:47 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: Agreement Was Announced on Dec. 19

4. Juli 2025, 15:47 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4. Juli 2025, 15:46 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4. Juli 2025, 14:30 UTC

Akquisitionen, Fusionen, Übernahmen

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4. Juli 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4. Juli 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4. Juli 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4. Juli 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. Juli 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4. Juli 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4. Juli 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4. Juli 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4. Juli 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4. Juli 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Juli 2025, 12:02 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

Peer-Vergleich

Kursveränderung

Cerus Corp Prognose

Kursziel

By TipRanks

203.25% Vorteil

12-Monats-Prognose

Durchschnitt 4.67 USD  203.25%

Hoch 5 USD

Tief 4 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cerus Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

1.3 / 1.36Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

146 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.